Drug Trial Radar · NCT04327440
RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,691
Actual
Start
Feb 4, 2020
Primary completion
Jun 30, 2021
Study completion Jun 30, 2021
Sponsor
- Lead sponsor
- Michigan State UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kamuzu University of Health Sciences; University of Maryland, Baltimore; Boston University; National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Mar 31, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 7 months, up to 10 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The overall goal of this study is to assess the impact of RTS,S (malaria) vaccination and PBO nets on malaria infection and transmission, independently and how they interact when they are introduced together. The specific objectives for the study are as follows: 1. To estimate the impact of PBO nets and RTS,S vaccine on Plasmodium infection prevalence and transmission, independently and how they interact when they are introduced together in Malawi (Phase 1). 2. To assess the feasibility of evaluating the impact of RTS,S vaccine and PBO nets independently in a larger scale future study.
Conditions
- Malaria, Malaria Vaccine, Insecticide-treated Bednets
Interventions
RTS,S/AS01 malaria vaccineBiological
Malaria vaccine: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen combined with an adjuvant. The Phase 3 trial of three doses administered to 5-17-month-olds confirmed moderate protection, with overall efficacy estimates of 50.4% against clinical malaria and 34.8% against severe malaria after three doses. Efficacy, which waned over time, was marginally improved by boosting at 18 months. The European Medicines Agency adopted a positive scientific opinion of the vaccine for use outside of the European Union. The World Health Organization has created the Malaria Vaccine Implementation Program (MVIP) and selected Malawi as one of the sites to explore the feasibility, efficacy and safety of RTS,S vaccination in the context of routine use.
PBO bed netsOther
PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting
Primary outcomes
What the sponsor says the trial is designed to measure.
- Malaria infection prevalenceTime frame: 6 months/cohort, 4 cohorts in Phase 1
- Anopheles species abundanceTime frame: 6 months/cohort, 4 cohorts in Phase 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Malawi College of Medicine
Blantyre, Malawi
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.